{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:39:30Z","timestamp":1789666770315,"version":"4.0.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011975","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000}}],"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016285","name":"TDR","doi-asserted-by":"publisher","award":["TSA"],"award-info":[{"award-number":["TSA"]}],"id":[{"id":"10.13039\/100016285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016285","name":"TDR","doi-asserted-by":"publisher","award":["TSA"],"award-info":[{"award-number":["TSA"]}],"id":[{"id":"10.13039\/100016285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001822","name":"\u00d6sterreichischen Akademie der Wissenschaften","doi-asserted-by":"publisher","award":["23357"],"award-info":[{"award-number":["23357"]}],"id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Target Product Profiles (TPPs) are instrumental to help optimise the design and development of therapeutics, vaccines, and diagnostics \u2013 these products, in order to achieve the intended impact, should be aligned with users\u2019 preferences and needs. However, patients are rarely involved as key stakeholders in building a TPP.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methodology<\/jats:title><jats:p>Thirty-three cutaneous leishmaniasis (CL) patients from Brazil, Colombia, and Austria, infected with New-World<jats:italic>Leishmania<\/jats:italic>species, were recruited using a maximum variation approach along geographic, sociodemographic and clinical criteria. Semi-structured interviews were conducted in the respective patient\u2019s mother tongue. Transcripts, translated into English, were analysed using a framework approach. We matched disease experiences, preferences, and expectations of CL patients to a TPP developed by DND<jats:italic>i<\/jats:italic>(Drug for Neglected Diseases<jats:italic>initiative<\/jats:italic>) for CL treatment.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Principal findings<\/jats:title><jats:p>Patients\u2019 preferences regarding treatments ranged from specific efficacy and safety endpoints to direct and significant indirect costs. Respondents expressed views about trade-offs between efficacy and experienced discomfort\/adverse events caused by treatment. Reasons for non-compliance, such as adverse events or geographical and availability barriers, were discussed. Considerations related to accessibility and affordability were relevant from the patients\u2019 perspective.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions\/Significance<\/jats:title><jats:p>NTDs affect disadvantaged populations, often with little access to health systems. Engaging patients in designing adapted therapies could significantly contribute to the suitability of an intervention to a specific context and to compliance, by tailoring the product to the end-users\u2019 needs. This exploratory study identified preferences in a broad international patient spectrum. It provides methodological guidance on how patients can be meaningfully involved as stakeholders in the construction of a TPP of therapeutics for NTDs. CL is used as an exemplar, but the approach can be adapted for other NTDs.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pntd.0011975","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T18:32:31Z","timestamp":1708540351000},"page":"e0011975","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-2919","authenticated-orcid":true,"given":"Mar\u00eda del Mar","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-9676","authenticated-orcid":true,"given":"Astrid C.","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gl\u00e1ucia","family":"Cota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Denkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kutyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"L\u00f3pez-Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Plugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Walochnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"pntd.0011975.ref001","volume-title":"Major Infectious Diseases.","author":"C Fitzpatrick","year":"2017","edition":"3"},{"key":"pntd.0011975.ref002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17441692.2012.699088","article-title":"Aligning new interventions with developing country health systems: Target product profiles, presentation, and clinical trial design.","volume":"7","author":"A Brooks","year":"2012","journal-title":"Glob Public Health"},{"key":"pntd.0011975.ref003","first-page":"82","article-title":"An evaluation of GAVI Alliance efforts to introduce new vaccines via the Accelerated Development and Introduction Plans (ADIPs) and the Hib Initiative (HI).","author":"J Milstien","year":"2007","journal-title":"GAVI\/Norad"},{"key":"pntd.0011975.ref004","article-title":"Product profile directory","author":"TDR","year":"2019","journal-title":"TDR, Special Programme for Research and Training in Tropical Diseases Product Profile Directory [Internet]"},{"key":"pntd.0011975.ref005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12961-019-0507-1","article-title":"Analysis of the Health Product Profile Directory\u2014a new tool to inform priority-setting in global public health.","volume":"17","author":"RF Terry","year":"2019","journal-title":"Health Res Policy Syst."},{"key":"pntd.0011975.ref006","author":"Food and Drug Administration (FDA).","year":"2007","journal-title":"Guidance for Industry and Review Staff Target Product Profile\u2014A Strategic Development Process Tool"},{"key":"pntd.0011975.ref007","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s11095-007-9511-1","article-title":"Pharmaceutical quality by design: product and process development, understanding, and control","volume":"25","author":"LX Yu","year":"2008","journal-title":"Pharm Res"},{"key":"pntd.0011975.ref008","doi-asserted-by":"crossref","first-page":"e1000398","DOI":"10.1371\/journal.pmed.1000398","article-title":"A research agenda for malaria eradication: vaccines","volume":"8","author":"malERA Consultative Group on Vaccines","year":"2011","journal-title":"PLoS Med"},{"key":"pntd.0011975.ref009","author":"Drugs for Neglected Diseases initiative (DNDi).","year":"2009","journal-title":"Target Product Profiles (TPP) | DNDi. In: Drugs for Neglected Diseases initiative (DNDi) [Internet]"},{"key":"pntd.0011975.ref010","article-title":"Target product profiles (TPPs) for diagnostic tests.","author":"Foundation for Innovative New Diagnostics (FIND).","journal-title":"Target Product Profiles [Internet]. 2017"},{"key":"pntd.0011975.ref011","first-page":"7","article-title":"Innovation in neglected tropical disease drug discovery and development","author":"H-B Weng","year":"2018","journal-title":"Infect Dis Poverty"},{"key":"pntd.0011975.ref012","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"E Chatelain","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"pntd.0011975.ref013","volume-title":"Diagnostics for neglected tropical diseases: Defining the best tools through target product profiles","author":"PATH","year":"2015"},{"key":"pntd.0011975.ref014","doi-asserted-by":"crossref","first-page":"e00103","DOI":"10.1016\/j.parepi.2019.e00103","article-title":"Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases.","volume":"5","author":"I Cruz","year":"2019","journal-title":"Parasite Epidemiology and Control."},{"key":"pntd.0011975.ref015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12916-020-01582-1","article-title":"Target Product Profiles for medical tests: a systematic review of current methods.","volume":"18","author":"P Cocco","year":"2020","journal-title":"BMC Med."},{"key":"pntd.0011975.ref016","volume-title":"How-to guide for patient engagement in the early discovery and preclinical phases","author":"Patient focused medicines development","year":"2020"},{"key":"pntd.0011975.ref017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejpb.2022.06.006","article-title":"Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes\u2013A proposed roadmap","volume":"177","author":"S Stegemann","year":"2022","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"pntd.0011975.ref018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5588\/ijtld.17.0312","article-title":"Which attributes within target product profiles for tuberculosis diagnostics are the most important to focus on?","volume":"22","author":"T Adepoyibi","year":"2018","journal-title":"Int J Tuberc Lung Dis."},{"key":"pntd.0011975.ref019","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/infdis\/jiu821","article-title":"Defining the Needs for Next Generation Assays for Tuberculosis","volume":"211","author":"CM Denkinger","year":"2015","journal-title":"The Journal of Infectious Diseases"},{"key":"pntd.0011975.ref020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.9745\/GHSP-D-13-00147","article-title":"Preferences for a potential longer-acting injectable contraceptive: perspectives from women, providers, and policy makers in Kenya and Rwanda.","volume":"2","author":"EE Tolley","year":"2014","journal-title":"Glob Health Sci Pract"},{"key":"pntd.0011975.ref021","unstructured":"World Health Organization. Leishmaniasis fact sheet, http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/, accessed 2018-04-18. In: WHO [Internet]. 2018 [cited 18 Apr 2018]. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/."},{"key":"pntd.0011975.ref022","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s40265-013-0132-1","article-title":"Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.","volume":"73","author":"B Monge-Maillo","year":"2013","journal-title":"Drugs"},{"key":"pntd.0011975.ref023","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis.","volume":"8","author":"M Pinart","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"pntd.0011975.ref024","doi-asserted-by":"crossref","first-page":"e0149697","DOI":"10.1371\/journal.pone.0149697","article-title":"The cure rate after placebo or no therapy in American cutaneous leishmaniasis: a systematic review and meta-analysis.","volume":"11","author":"GF Cota","year":"2016","journal-title":"PLoS One."},{"key":"pntd.0011975.ref025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1808-8694(15)31181-2","article-title":"Mucosal leishmaniasis: epidemiological and clinical aspects","volume":"73","author":"M Miranda Lessa","year":"2007","journal-title":"Brazilian Journal of Otorhinolaryngology"},{"key":"pntd.0011975.ref026","doi-asserted-by":"crossref","first-page":"e021372","DOI":"10.1136\/bmjopen-2017-021372","article-title":"An international qualitative study exploring patients\u2019 experiences of cutaneous leishmaniasis: study set-up and protocol","volume":"8","author":"AC Erber","year":"2018","journal-title":"BMJ Open"},{"key":"pntd.0011975.ref027","doi-asserted-by":"crossref","first-page":"e0007996","DOI":"10.1371\/journal.pntd.0007996","article-title":"Patients\u2019 preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study.","volume":"14","author":"AC Erber","year":"2020","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"pntd.0011975.ref028","first-page":"900","article-title":"[A case of leishmaniasis in Lower Austria].","volume":"115","author":"J. Beyreder","year":"1965","journal-title":"Wien Med Wochenschr"},{"key":"pntd.0011975.ref029","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0140-6736(89)92895-X","article-title":"Suspected autochthonous kala-azar in Austria","volume":"1","author":"H Kollaritsch","year":"1989","journal-title":"Lancet"},{"key":"pntd.0011975.ref030","unstructured":"Srivastava A,Thomson SB. Framework Analysis: A Qualitative Methodology for Applied Policy Research. Rochester, NY: Social Science Research Network; 2009 Jan. Report No.: ID 2760705. Available: https:\/\/papers.ssrn.com\/abstract=2760705."},{"key":"pntd.0011975.ref031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research.","volume":"13","author":"NK Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"pntd.0011975.ref032","author":"DNDi","year":"2020","journal-title":"Target product profile for cutaneous leishmaniasis | DNDi"},{"key":"pntd.0011975.ref033","doi-asserted-by":"crossref","first-page":"e0007092","DOI":"10.1371\/journal.pntd.0007092","article-title":"Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates.","volume":"13","author":"F Bailey","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011975.ref034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12889-018-5260-9","article-title":"Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review.","volume":"18","author":"I Bennis","year":"2018","journal-title":"BMC Public Health"},{"key":"pntd.0011975.ref035","doi-asserted-by":"crossref","first-page":"e0242494","DOI":"10.1371\/journal.pone.0242494","article-title":"Psycho-social impacts, experiences and perspectives of patients with Cutaneous Leishmaniasis regarding treatment options and case management: An exploratory qualitative study in Tunisia.","volume":"15","author":"A Boukthir","year":"2020","journal-title":"PLoS One"},{"key":"pntd.0011975.ref036","doi-asserted-by":"crossref","first-page":"180","DOI":"10.18502\/jad.v12i2.44","article-title":"Lived Experiences of Patients Suffering from Acute Old World Cutaneous Leishmaniasis: A Qualitative Content Analysis Study from Iran","volume":"12","author":"A Khatami","year":"2018","journal-title":"J Arthropod Borne Dis."},{"key":"pntd.0011975.ref037","doi-asserted-by":"crossref","first-page":"e0223313","DOI":"10.1371\/journal.pone.0223313","article-title":"The impact of leishmaniasis on mental health and psychosocial well-being: A systematic review.","volume":"14","author":"M Pires","year":"2019","journal-title":"PLOS ONE."},{"key":"pntd.0011975.ref038","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3201\/eid1104.040945","article-title":"Social impact of leishmaniasis, Afghanistan.","volume":"11","author":"R Reithinger","year":"2005","journal-title":"Emerging Infect Dis"},{"key":"pntd.0011975.ref039","volume-title":"Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021\u20132030.","author":"MM Ntuli","year":"2021"},{"key":"pntd.0011975.ref040","first-page":"135","article-title":"Anthropological perspectives on injections: a review","volume":"78","author":"AV Reeler","year":"2000","journal-title":"Bull World Health Organ"},{"key":"pntd.0011975.ref041","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.puhe.2006.05.004","article-title":"Population beliefs about the efficacy of injections in Pakistan\u2019s Sindh province.","volume":"120","author":"NZ Janjua","year":"2006","journal-title":"Public Health."},{"key":"pntd.0011975.ref042","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.15-0408","article-title":"Social and Economic Burden of Human Leishmaniasis","volume":"94","author":"I Okwor","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011975.ref043","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12879-022-07204-w","article-title":"Barriers to cutaneous leishmaniasis care faced by indigenous communities of rural areas in Colombia: a qualitative study.","volume":"22","author":"MM Bautista-Gomez","year":"2022","journal-title":"BMC Infect Dis"},{"key":"pntd.0011975.ref044","first-page":"779","article-title":"Cutaneous leishmaniasis in Guatemala: people\u2019s knowledge, concepts and practices.","volume":"94","author":"BA Arana","year":"2000","journal-title":"null."},{"key":"pntd.0011975.ref045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(16)30171-4","article-title":"Neglected tropical diseases: progress towards addressing the chronic pandemic","volume":"389","author":"DH Molyneux","year":"2017","journal-title":"The Lancet"},{"key":"pntd.0011975.ref046","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/RRTM.S278138","article-title":"Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review.","volume":"12","author":"G Grifferty","year":"2021","journal-title":"RRTM."},{"key":"pntd.0011975.ref047","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/2168479015580384","article-title":"Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action.","volume":"49","author":"A Hoos","year":"2015","journal-title":"Ther Innov Regul Sci"},{"key":"pntd.0011975.ref048","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jval.2016.04.009","article-title":"Increasing Patient Involvement in Drug Development.","volume":"19","author":"MM Lowe","year":"2016","journal-title":"Value in Health"},{"key":"pntd.0011975.ref049","first-page":"106","article-title":"Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. International Journal for Parasitology","volume":"11","author":"D Caridha","year":"2019","journal-title":"Drugs and Drug Resistance"},{"key":"pntd.0011975.ref050","first-page":"935","article-title":"Evaluation of scars and treatment preferences in subjects with Cutaneous Leishmaniasis treated with pentavalent antimonials, thermotherapy or thermotherapy in combination with miltefosine, a multicenter study Colombia and Peru. WorldLeish 7 Proceedings and abstracts book.","author":"L L\u00f3pez","year":"2022","journal-title":"Cartagena, Colombia"},{"key":"pntd.0011975.ref051","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1207\/S15327957PSPR0403_2","article-title":"Three Kinds of Opinion Comparison: The Triadic Model.","volume":"4","author":"J Suls","year":"2000","journal-title":"Pers Soc Psychol Rev"},{"key":"pntd.0011975.ref052","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","article-title":"Discrete choice experiments in health care","volume":"328","author":"M. Ryan","year":"2004","journal-title":"BMJ"},{"key":"pntd.0011975.ref053","first-page":"55","article-title":"Using discrete choice experiments to value health care programmes: current practice and future research reflections.","volume":"2","author":"M Ryan","year":"2003","journal-title":"Appl Health Econ Health Policy"},{"key":"pntd.0011975.ref054","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.3390\/ijerph18094916","article-title":"Investigating Patients\u2019 Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine.","volume":"18","author":"A Torbica","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"pntd.0011975.ref055","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/cpt.1231","article-title":"Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs","volume":"105","author":"EAF Holmes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"pntd.0011975.ref056","doi-asserted-by":"crossref","first-page":"23814683211039457","DOI":"10.1177\/23814683211039457","article-title":"Measuring Meaningful Benefit-Risk Tradeoffs to Promote Patient-Focused Drug Development in Prader-Willi Syndrome","volume":"6","author":"J-H Tsai","year":"2021","journal-title":"A Discrete-Choice Experiment. MDM Policy Pract"},{"key":"pntd.0011975.ref057","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40271-021-00544-w","article-title":"Understanding Attributes that Influence Physician and Caregiver Decisions About Neurotechnology for Pediatric Drug-Resistant Epilepsy: A Formative Qualitative Study to Support the Development of a Discrete Choice Experiment.","volume":"15","author":"G Apantaku","year":"2022","journal-title":"Patient"},{"key":"pntd.0011975.ref058","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4135\/9781848608191.d34","volume-title":"Qualitative Research Practice. SAGE Publications","author":"G. Gobo","year":"2004"},{"key":"pntd.0011975.ref059","year":"2022","journal-title":"WHO. Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases."},{"key":"pntd.0011975.ref060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0140-6736(22)00161-1","article-title":"Neglected tropical diseases: ending the neglect of populations","volume":"399","author":"T. Lancet","year":"2022","journal-title":"The Lancet"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011975","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T04:25:52Z","timestamp":1731385552000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011975"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Deye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011975","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011975","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}